BridgeBio Oncology Therapeutics (BBOT) Capital Expenditures (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Capital Expenditures of $24000.0 for Q1 2026, down 88.46% sequentially from $208000.0 in Q4 2025, and down 22.58% YoY from $31000.0 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Capital Expenditures (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Capital Expenditures for 3 years, with the latest figure at $24000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 22.58% year-over-year to $24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273000.0 (changed N/A YoY) and the FY2025 annual result came in at $606000.0, up 1136.73% from the prior year.
- Capital Expenditures eased to $24000.0 in Q1 2026 per BBOT's latest filing, from $208000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $208000.0 in Q4 2025 and troughed at $10000.0 in Q4 2024.
- A 3-year average of $68250.0 and a median of $27500.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures jumped 1980.0% in 2025, then retreated 22.58% in 2026.
- Over 3 years, Capital Expenditures stood at $10000.0 in 2024, then surged by 1980.0% to $208000.0 in 2025, then sank by 88.46% to $24000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $24000.0, $208000.0, and $31000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Mn |
| Jun 30, 2026 | 1.56 Mn |
| Mar 31, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | 208,000.00 |
| Dec 31, 2025 | 208,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |